1. Foundations: Understanding Menopause
Pedagogy: This lesson uses domain-mapping and validated instrument selection — training systematic symptom capture that prevents the under-recognition commonly seen in primary care.
Learning Objectives
- Identify the seven principal symptom domains of menopause: vasomotor, genitourinary, psychological, musculoskeletal, sexual, sleep, and cardiometabolic.
- Describe the typical duration, severity, and natural history of vasomotor symptoms including ethnic variation.
- Recognise that menopausal symptoms are heterogeneous and influenced by biological, psychological, and sociocultural factors.
- Select and apply validated symptom assessment tools (Greene Climacteric Scale, MRS, MENQOL) in clinical practice.
Key Facts
Seven Symptom Domains
Menopausal symptoms span multiple organ systems. The symptom burden is heterogeneous and influenced by biological factors (genetics, BMI, ethnicity), psychological factors (stress, pre-existing mental health), and sociocultural context (1,2).
| Domain | Key Symptoms | Clinical Notes |
|---|---|---|
| Vasomotor | Hot flushes, night sweats | 80% prevalence; median 7.4 yrs; 11–46% moderate-to-severe; CVD biomarker |
| Genitourinary (GSM) | Vaginal dryness, dyspareunia, urinary frequency, recurrent UTI | Progressive; does NOT resolve spontaneously; >50% affected |
| Psychological | Low mood, anxiety, irritability, concentration difficulty | Bidirectional with sleep; MHT not for clinical depression or dementia prevention |
| Musculoskeletal | Joint pain, stiffness, sarcopenia | Often under-recognised as menopausal; assess for sarcopenia alongside osteoporosis |
| Sexual | Reduced desire (HSDD), arousal difficulty | Multifactorial; oral MHT may ↑ SHBG and ↓ bioavailable testosterone |
| Sleep | Insomnia, fragmented sleep | May be secondary to VMS or independent; CBT-I effective |
| Cardiometabolic | Rising BP, adverse lipids, insulin resistance | Menopause = cardiometabolic turning point; use consultation for QRISK3 |
Vasomotor Symptoms: Duration and Ethnic Variation
Up to 80% of women experience VMS. The SWAN study reported median total VMS duration of 7.4 years — longer in women with early perimenopause onset. Ethnicity influences prevalence: African-American women report the longest duration (median 10.1 years), whilst Asian women report the fewest (1).
VMS are not merely a quality-of-life nuisance. A meta-analysis of over 213,000 women demonstrated that symptomatic women had higher risks of CHD (RR 1.34), stroke (RR 1.30), and composite CVD (RR 1.48) compared with asymptomatic women (3).
Validated Assessment Tools
| Tool | Measures | Format | Best For |
|---|---|---|---|
| Greene Climacteric Scale | 21 items: VMS, psychological, somatic, sexual | Self-report; Likert scale | UK clinical practice |
| MRS | 11 items: somatic, psychological, urogenital | Self-report; 5-point severity | International; 25+ languages |
| MENQOL | 29 items: vasomotor, psychosocial, physical, sexual | Bothered/not + severity | QoL impact; clinical trials |
Clinical Pearl
Menopausal symptoms are frequently vague and multi-system. Mood affects sleep, which impacts relationships and sexual function — and vice versa. A structured symptom assessment using a validated tool (MRS or Greene Scale) prevents under-recognition.
Clinical Pearl
VMS are independently associated with increased cardiovascular risk (RR 1.34 for CHD). Treat VMS AND simultaneously assess CVD risk factors — this is the precision menopause approach.
Case-Based Examples
Case 1: Low mood on sertraline — missed menopausal presentation
Presentation: A 52-year-old presents with low mood, fatigue, poor concentration, and irritability. Started on sertraline 6 weeks ago with minimal improvement. Periods stopped 8 months ago. No one has asked about VMS or urogenital symptoms.
Question: What additional history should you take and how would a structured symptom assessment change management?
Model Answer: Screen for VMS (hot flushes, night sweats, sleep quality), vaginal dryness, dyspareunia, joint pains, and libido. Use the Greene Climacteric Scale or MRS. If VMS are present, mood symptoms may be secondary to disrupted sleep from night sweats. The ESE guideline (2025): MHT is not routinely used for clinical depression, but where mood coexists with VMS and is temporally related to the transition, a trial of HRT (with mood reassessment at 3 months) may be more appropriate than an ineffective SSRI. Sertraline should not be stopped abruptly; plan jointly with the patient.
Case 2: Severe VMS in a Black British woman with cardiometabolic risk
Presentation: A 48-year-old Black British woman presents with severe VMS (15+/day), joint pains, low mood, and 6 kg weight gain. She has read that "menopause symptoms don't last long." Family history of T2DM. BMI 33.
Question: Counsel her about expected duration and significance, incorporating ethnicity-specific data and cardiometabolic risk assessment.
Model Answer: Counter misinformation: SWAN data show median VMS duration 7.4 years; African-American women experience the longest (median 10.1 years). The combination of severe VMS, BMI >30, central adiposity, and family history of T2DM = significant cardiometabolic risk. VMS independently associated with CVD (RR 1.48 composite). Conduct precision menopause assessment: QRISK3, fasting lipids, HbA1c, BP, waist circumference. Transdermal HRT preferred (BMI >30 — no VTE increase). IMS 2025: 5–10% weight loss improves insulin resistance; MHT attenuates fat redistribution but is not a weight-loss treatment. Consider statin if QRISK3 ≥10%.
Self-Assessment Questions
PLAB/MLA Which statement about GSM is correct?
A. GSM typically resolves spontaneously within 2–3 years
B. GSM affects approximately 10% of postmenopausal women
C. GSM is progressive and does not resolve without treatment
D. Systemic HRT alone is always sufficient for GSM
E. GSM only affects vaginal epithelium
Answer: C. GSM is progressive and chronic. Unlike VMS, it does not resolve spontaneously. It affects >50% of postmenopausal women, involves genital, urinary, and sexual domains, and may require topical vaginal oestrogen even with systemic HRT.
MRCGP Managing mood symptoms without VMS in a 54-year-old
A 54-year-old with controlled hypertension and BMI 31 reports sleep disturbance, low mood, and fatigue. She denies VMS. Periods stopped 2 years ago. She requests HRT for mood.
Discuss your approach including use of a symptom assessment tool.
Model Answer: Apply validated tool (MRS/Greene) to uncover unreported VMS or urogenital symptoms. If VMS present alongside mood, HRT may indirectly improve mood via better sleep. If no VMS and isolated mood symptoms, ESE 2025: MHT should not routinely be used for clinical depression. Consider PHQ-9/GAD-7 and offer CBT or antidepressant. NICE NG23 recommends menopause-specific CBT for VMS, sleep, and low mood. Given hypertension and BMI, if HRT is considered: transdermal oestrogen preferred. Conduct cardiometabolic assessment: QRISK3, fasting lipids, HbA1c. Demonstrates holistic menopause care, not sole HRT focus.
Professor Ethnic variation in VMS: SWAN methodology critique
SWAN reports significant ethnic variation in menopausal symptom prevalence and duration. Critically evaluate strengths and limitations of using prospective cohort data for diverse populations.
Model Answer: Strengths: multi-ethnic, multi-site longitudinal design; >3,000 women; standardised symptom ascertainment; biological sampling; 20+ years follow-up. African-American women: longest VMS (10.1 yrs vs 6.5 white). Limitations: self-selection bias; self-reported symptoms (not objective skin conductance); difficulty disentangling menopausal symptoms from ageing/comorbidity/psychosocial stressors more prevalent in disadvantaged groups; limited generalisability of US ethnic categories to UK populations (South Asian experience under-represented). Cohort data establish associations, not causation. No ethnicity-stratified RCT data means treatment recommendations are extrapolated. The Closing the Women's Health Gap report highlights ethnicity-related access disparities compound these evidence gaps.
Take-Away Messages
- Menopausal symptoms span seven domains: VMS, GSM, psychological, musculoskeletal, sexual, sleep, cardiometabolic.
- VMS affect 80% of women; median duration 7.4 years; significantly longer in Black women (10.1 years).
- GSM is progressive, chronic, and does NOT resolve spontaneously — ongoing treatment required.
- Use validated tools (Greene Climacteric Scale, MRS, MENQOL) to systematically capture the full symptom profile.
- VMS are independently associated with increased cardiovascular risk — treat symptoms AND assess CVD risk simultaneously.